Despite such inconsistent results of previous clinical studies, IFN-γ is still tested as a treatment for HER-2 positive breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and soft tissue sarcoma (ClinicalTrials.gov: NCT03112590, NCT02948426 and NCT03056599). Here, IFNG is linked to ovarian cancer.